DeepMed Research

NeuroDerm Ltd.

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Subsidiary

Established: 2003-01-01

Employees: 101

Market Cap: -

Website: http://www.neuroderm.com

Clinical Trials

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

Phase 3

Active, not recruiting

Conditions: Parkinson's Disease

Interventions: Combination Product: Placebo for SC infusion
Drug: Oral IR-LD/CD
Combination Product: ND0612 Solution for SC infusion
Drug: Placebo for Oral IR-LD/CD

First Posted Date: 2019-07-05

Last Posted Date: 2025-05-21

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 381

Registration Number: NCT04006210

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
🇺🇸
Visionary Investigators Network, Aventura, Florida, United States

and more 100 locations

A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

Phase 3

Withdrawn

Conditions: Parkinson

Interventions: Combination Product: ND0612
Combination Product: CLES

First Posted Date: 2018-03-12

Last Posted Date: 2018-11-23

Lead Sponsor: NeuroDerm Ltd.

Registration Number: NCT03462043

Locations: 🇮🇹
91601, Roma, Italy

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Phase 3

Withdrawn

Conditions: Parkinson's Disease

Interventions: Drug: ND0612
Drug: Placebo

First Posted Date: 2016-05-25

Last Posted Date: 2019-12-10

Lead Sponsor: NeuroDerm Ltd.

Registration Number: NCT02782481

Locations: 🇮🇱
Haddasah Ein Kerem Medical center, Jerusalem, Israel

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

Phase 2

Active, not recruiting

Conditions: Parkinson's Disease

Interventions: Drug: ND0612

First Posted Date: 2016-04-01

Last Posted Date: 2024-01-19

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 214

Registration Number: NCT02726386

Locations: 🇺🇸
Parkinsons Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, United States
🇮🇹
IRCCS San Raffaele Pisana, Rome, Italy
🇺🇸
Henry Ford Hospital, West Bloomfield, Michigan, United States

and more 53 locations

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: ND0612
Drug: LCIG

First Posted Date: 2015-11-16

Last Posted Date: 2024-01-18

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 36

Registration Number: NCT02604914

Locations: 🇬🇧
Quotient Clinical LTD, Ruddington, Nottingham, United Kingdom

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: ND0612 (Levodopa/Carbidopa solution)
Drug: ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD

First Posted Date: 2015-10-16

Last Posted Date: 2023-05-25

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 38

Registration Number: NCT02577523

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
QUEST Research Institute, Farmington Hills, Michigan, United States

and more 8 locations

A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Levodopa/Carbidopa (Sinemet)

First Posted Date: 2015-07-01

Last Posted Date: 2015-07-01

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 6

Registration Number: NCT02486432

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: LD/CD SC solution
Drug: Entacapone

First Posted Date: 2014-03-26

Last Posted Date: 2024-04-29

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 16

Registration Number: NCT02096601

Locations: 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱
Hadassah Medical Center, Jerusalem, Israel

A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Levodopa and carbidopa
Drug: Placebo

First Posted Date: 2013-06-21

Last Posted Date: 2024-01-18

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 30

Registration Number: NCT01883505

Locations: 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱
Rabin Medical Center, Petah Tikva, Israel

A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Levodopa/carbidopa solution for SC administration
Drug: Placebo

First Posted Date: 2012-11-14

Last Posted Date: 2024-05-01

Lead Sponsor: NeuroDerm Ltd.

Target Recruit Count: 8

Registration Number: NCT01725802

Locations: 🇮🇱
Hadassah Medical Center, Jerusalem, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy